MarketCap
Facebook
X
TelegramQuartalsbericht 2025-Q3
hinzugefügt 03.11.2025
Land |
 Kanada |
IPO-Jahr |
2014 |
Branche |
Pharmaeinzelhändler |
Börse |
NASDAQ GLOBAL |
Anteile |
77.9 M |
Marktkapitalisierung |
$ 4.63 B |
EBITDA (LTM) |
$ -216 M |
P/E (LTM) |
-15.14 |
P/S (LTM) |
268.77 |
EPS (LTM) |
-3.86 |
Andere Aktien der Branche "Pharmaeinzelhändler"
| Name | Preis | % 24h | Marktkapitalisierung | Börse | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
$ 4.34 | 9.32 % | $ 10.4 B | Nasdaq Capital Market |  Australia |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market |  USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market |  France |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
Akari Therapeutics, Plc
AKTX
|
$ 5.46 | 6.64 % | $ 368 B | Nasdaq Capital Market |  Britain |
 |
Aligos Therapeutics
ALGS
|
$ 6.61 | -13.71 % | $ 65.3 M | Nasdaq Global Select Market | USA |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 310.78 | -2.92 % | $ 40.7 B | Nasdaq Global Select Market,SPB | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 22.7 | 4.08 % | $ 1.06 B | Nasdaq Global Select Market | USA |
 |
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | USA |
 |
BioNTech SE
BNTX
|
$ 104.52 | 2.35 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 3.04 | -1.3 % | $ 5 M | NYSE American |  Israel |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | Canada |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
BioXcel Therapeutics
BTAI
|
$ 1.18 | 9.81 % | $ 14.4 M | Nasdaq Global Select Market,SPB | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Akebia Therapeutics
AKBA
|
$ 1.44 | 6.67 % | $ 370 M | Nasdaq Global Market | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Aquestive Therapeutics
AQST
|
$ 4.36 | 2.35 % | $ 466 M | Nasdaq Global Market | USA |
 |
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
Arcutis Biotherapeutics
ARQT
|
$ 24.65 | 1.9 % | $ 3.14 B | Nasdaq Global Select Market,SPB | USA |
 |
Burford Capital Limited
BUR
|
$ 5.0 | 6.96 % | $ 792 M | NYSE | Britain |
 |
Celldex Therapeutics
CLDX
|
$ 34.97 | 3.28 % | $ 2.32 B | Nasdaq Global Select Market | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
- | -2.5 % | $ 5.88 M | Nasdaq Capital Market | USA |
 |
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | USA |
 |
Cabaletta Bio
CABA
|
$ 3.37 | -4.4 % | $ 339 M | Nasdaq Global Select Market | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.65 | 2.48 % | $ 439 M | Nasdaq Global Select Market | Britain |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | USA |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Cidara Therapeutics
CDTX
|
- | - | $ 1.41 B | Nasdaq Global Market | USA |
 |
CymaBay Therapeutics
CBAY
|
- | - | $ 3.45 B | Nasdaq Global Select Market | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |